A pilot study: potential role of nutrient vitamin D in prostate cancer patients with rising PSA after definitive therapy

被引：0
|
作者：
Choo, R.
Woo, T.
Veith, R.
Jamieson, M.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
[3] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：250 / 250
页数：1
相关论文
共 50 条
  • [31] A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy
    Pruthi, RS
    Derksen, JE
    Moore, D
    BJU INTERNATIONAL, 2004, 93 (03) : 275 - 278
  • [32] A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer
    Paller, C. J.
    Ye, X.
    Wozniak, P. J.
    Gillespie, B. K.
    Sieber, P. R.
    Greengold, R. H.
    Stockton, B. R.
    Hertzman, B. L.
    Efros, M. D.
    Roper, R. P.
    Liker, H. R.
    Carducci, M. A.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (01) : 50 - 55
  • [33] Clinical Experience with 18F-fluciclovine (Axumin) in Prostate Cancer Patients with a Rising PSA After Primary Treatment
    Muhleman, Mitchel
    Chong, Julio
    Ahmed, Jalal
    Stock, Richard
    Tewari, Ashutosh
    Doucette, John
    Oh, William
    Kostakoglu, Lale
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [34] The effect of PSA frequency and duration on PSA doubling time (PSADT) calculations in men with biochemically recurrent prostate cancer (BRPC) after definitive local therapy.
    Paller, Channing Judith
    Xie, Sherlly
    Olatoye, Dare
    Denmeade, Samuel R.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    Carducci, Michael Anthony
    Rosner, Gary L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer
    C J Paller
    X Ye
    P J Wozniak
    B K Gillespie
    P R Sieber
    R H Greengold
    B R Stockton
    B L Hertzman
    M D Efros
    R P Roper
    H R Liker
    M A Carducci
    Prostate Cancer and Prostatic Diseases, 2013, 16 : 50 - 55
  • [36] Management of prostate-specific antigen (PSA) recurrence after initial definitive local therapy for prostate cancer: Updated results from the compare registry
    Sartor, Oliver
    Scardino, Peter T.
    McLeod, David G.
    Schelhammer, Paul F.
    D'Amico, Anthony V.
    Halabi, Susan
    JOURNAL OF UROLOGY, 2007, 177 (04): : 70 - 70
  • [37] A Pilot Study of Quality of Life of Patients with Hormone-refractory Prostate Cancer after Gene Therapy
    Terao, Shuji
    Shirakawa, Toshiro
    Acharya, Bishnu
    Miyata, Masahiro
    Hinata, Nobuyuki
    Tanaka, Kazushi
    Takenaka, Atsushi
    Hara, Isao
    Naoe, Michio
    Fuji, Kohzo
    Okegawa, Takatsugu
    Higashihara, Eiji
    Kamidono, Sadao
    Fujisawa, Masato
    Gotoh, Akinobu
    ANTICANCER RESEARCH, 2009, 29 (05) : 1533 - 1537
  • [38] End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
    A K Narang
    J Trieu
    N Radwan
    A Ram
    S P Robertson
    P He
    C Gergis
    E Griffith
    H Singh
    T A DeWeese
    S Honig
    A Annadanam
    S Greco
    C DeVille
    T McNutt
    T L DeWeese
    D Y Song
    P T Tran
    Prostate Cancer and Prostatic Diseases, 2017, 20 : 203 - 209
  • [39] End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
    Narang, A. K.
    Trieu, J.
    Radwan, N.
    Ram, A.
    Robertson, S. P.
    He, P.
    Gergis, C.
    Griffith, E.
    Singh, H.
    DeWeese, T. A.
    Honig, S.
    Annadanam, A.
    Greco, S.
    DeVille, C.
    McNutt, T.
    DeWeese, T. L.
    Song, D. Y.
    Tran, P. T.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (02) : 203 - 209
  • [40] Prognostic value of the modeled PSA kinetic parameter (KELIM) in prostate cancer patients with rising PSA after primary local therapy treated in a prospective phase III trial with ADT plus /- docetaxel
    Carrot, A.
    Elaidi, R-T.
    Colomban, O.
    Maillet, D.
    Tod, M.
    You, B.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S666 - S666
12345